NZ756507A - Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 - Google Patents
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15Info
- Publication number
- NZ756507A NZ756507A NZ756507A NZ75650718A NZ756507A NZ 756507 A NZ756507 A NZ 756507A NZ 756507 A NZ756507 A NZ 756507A NZ 75650718 A NZ75650718 A NZ 75650718A NZ 756507 A NZ756507 A NZ 756507A
- Authority
- NZ
- New Zealand
- Prior art keywords
- amino acid
- immunoconjugate
- seq
- domain
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to immunoconjugates comprising a human mutant interleukin-2 polypeptide bearing F42A, Y45A and L72G mutations relative to human IL-2 and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
Claims (34)
1. An immunoconjugate comprising (i) an antibody that binds to PD-1 and (ii) an IL-2 polypetide, wherein the IL-2 polypeptide is a mutant IL-2 polypeptide, 5 n the mutant IL-2 polypeptide is a human IL-2 molecule sing the amino acid substitutions F42A, Y45A and L72G (numbering ve to the human IL-2 sequence SEQ ID NO: 19).
2. An conjugate according to claim 1, wherein the IL-2 polypeptide is a mutant IL-2 polypeptide, 10 wherein the mutant IL-2 polypeptide is a human IL-2 molecule comprising the amino acid substitutions F42A, Y45A and L72G, the numbering being relative to the human IL-2 sequence SEQ ID NO: 19; and wherein the antibody comprises (a) a heavy chain variable region (VH) comprising a HVR-H1 comprising the amino acid sequence of SEQ ID NO:1, a HVR-H2 comprising the amino acid 15 sequence of SEQ ID NO:2, a HVR-H3 comprising the amino acid sequence of SEQ ID NO:3, and a FR-H3 sing the amino acid sequence of SEQ ID NO:7 at positions 71-73 ing to Kabat numbering, and (b) a light chain variable region (VL) comprising a HVR-L1 comprising the amino acid sequence of SEQ ID NO:4, a HVR-L2 comprising the amino acid ce of SEQ ID NO:5, and a HVR-L3 comprising the amino acid sequence of SEQ ID NO:6. 20
3. An immunoconjugate according to claim 1, wherein the IL-2 polypeptide is a mutant IL-2 polypeptide, wherein the mutant IL-2 polypeptide is a human IL-2 molecule comprising the amino acid substitutions F42A, Y45A and L72G, the numbering relative to the human IL-2 sequence SEQ ID NO: 19; and 25 wherein the antibody comprises (a) a heavy chain variable region (VH) comprising a HVR-H1 comprising the amino acid sequence of SEQ ID NO:8, a HVR-H2 comprising the amino acid sequence of SEQ ID NO:9, and a HVR-H3 comprising the amino acid sequence of SEQ ID NO:10, and (b) a light chain variable region (VL) comprising a HVR-L1 sing the amino acid sequence of SEQ ID NO:11, a HVR-L2 comprising the amino acid sequence of SEQ ID 30 NO:12, and a HVR-L3 comprising the amino acid sequence of SEQ ID NO:13.
4. An immunoconjugate according to claim 1, wherein the IL-2 ptide is a mutant IL-2 polypeptide, wherein the mutant IL-2 polypeptide is a human IL-2 molecule comprising the amino acid substitutions F42A, Y45A and L72G, the numbering relative to the human IL-2 sequence SEQ 5 ID NO: 19; and wherein the antibody comprises (a) a heavy chain variable region (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:14, and (b) a light chain variable region (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino 10 acid sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO: 17, and SEQ ID NO:18.
5. The immunoconjugate of any one of claims 1 to 4, wherein the mutant IL-2 polypeptide r comprises the amino acid substitution T3A and/or the amino acid substitution C125A.
6. The immunoconjugate of any one of claims 1 to 5, wherein the mutant IL-2 polypeptide 15 comprises the sequence of SEQ ID NO: 20.
7. The immunoconjugate of any one of claims 1 to 6, wherein the immunoconjugate comprises not more than one mutant IL-2 polypeptide.
8. The immunoconjugate of any one of claims 1 to 7, wherein the antibody comprises an Fc domain composed of a first and a second t. 20
9. The immunoconjugate of claim 8, wherein the Fc domain is an IgG class, ularly an IgG1 ss, Fc domain.
10. The immunoconjugate of claim 8 or 9, wherein the Fc domain is a human Fc domain.
11. The immunoconjugate of any one of claims 1 to 10, wherein the antibody is an IgG class, particularly an IgG1 ss immunoglobulin. 25
12. The immunoconjugate of any one of claims 8 to 11, wherein the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain.
13. The immunoconjugate of any one of claims 8 to 12, wherein in the CH3 domain of the first subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the CH3 domain of the first subunit which is positionable in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is ed with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the 5 CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first subunit is onable.
14. The immunoconjugate of any one of claims 8 to 13, wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the second subunit of the Fc domain the ne residue at position 407 is ed with a 10 valine residue (Y407V) and optionally the threonine residue at position 366 is replaced with a serine residue (T366S) and the leucine residue at position 368 is replaced with an alanine e ), the numbering being according to Kabat EU index.
15. The immunoconjugate of claim 14, wherein in the first subunit of the Fc domain additionally the serine residue at position 354 is replaced with a cysteine residue (S354C) or the glutamic 15 acid residue at position 356 is replaced with a cysteine residue (E356C), and in the second subunit of the Fc domain additionally the tyrosine residue at position 349 is replaced by a cysteine residue (Y349C), the numbering being according to Kabat EU index.
16. The immunoconjugate of any one of claims 8 to 15, wherein the mutant IL-2 polypeptide is fused at its amino-terminal amino acid to the carboxy-terminal amino acid of one of the subunits 20 of the Fc domain, particularly the first subunit of the Fc domain, optionally through a linker peptide.
17. The immunoconjugate of claim 16, n the linker e has the amino acid sequence of SEQ ID NO:21.
18. The immunoconjugate of any one of claims 8 to 16, wherein the Fc domain comprises one or 25 more amino acid substitution that reduces g to an Fc receptor, ularly an Fc? receptor, and/or effector function, particularly antibody-dependent cell-mediated cytotoxicity (ADCC).
19. The immunoconjugate of claim 18, wherein said one or more amino acid substitution is at one or more on selected from the group of L234, L235, and P329, the numbering being according to Kabat EU index.
20. The immunoconjugate of any one of claims 9 to 20, wherein each subunit of the Fc domain comprises the amino acid substitutions L234A, L235A and P329G, the numbering being according to the Kabat EU index.
21. The immunoconjugate of any one of claims 1 to 20, sing a polypeptide comprising an 5 amino acid sequence that is 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO:22, a polypeptide comprising an amino acid sequence that is 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO:23 or
22. SEQ ID NO:24, and a polypeptide comprising an amino acid sequence that is 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO:25. 10 22. The immunoconjugate of any one of claims 1 to 21, consisting of a mutant IL-2 polypeptide and an IgG1 immunoglobulin molecule, joined by a linker sequence.
23. One or more isolated polynucleotide encoding the immunoconjugate of any one of claims 1 to 22.
24. One or more vector, ularly expression vector, comprising the cleotide(s) of claim 15 23.
25. A host cell comprising the cleotide(s) of claim 23 or the vector(s) of claim 24, with the proviso that said host cell is not present in a human body.
26. A method of producing an immunoconjugate comprising a mutant IL-2 polypeptide and an antibody that binds to PD-1, comprising (a) culturing the host cell of claim 25 under conditions 20 suitable for the expression of the immunoconjugate, and optionally (b) recovering the immunoconjugate.
27. A pharmaceutical composition comprising the immunoconjugate of any one of claims 1 to 22 and a pharmaceutically acceptable r.
28. Use of the immunoconjugate of any one of claims 1 to 22 in the manufacture of a 25 medicament.
29. Use of the immunoconjugate of any one of claims 1 to 22 in the cture of a medicament for the ent of a disease.
30. The use of claim 29, wherein said disease is cancer.
31. A method of treating a disease in a non-human individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the conjugate of any one of claims 1 to 22 in a pharmaceutically acceptable form.
32. The method of claim 31, wherein said disease is cancer. 5
33. A method of ating the immune system of a non-human individual, comprising administering to said individual an effective amount of a composition comprising the immunoconjugate of any one of claims 1 to 22 in a pharmaceutically able form.
34. A immunoconjugate of any one of claims 1-22; one or more polynucleotides of claim 23; one or more vectors of claim 24; a host cell of claim 25; a method of any one of claims 26 and 10 31-33; a pharmaceutical composition of claim 27; or a use of any one of claims 28-30, substantially as described herein and with reference to any example thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17164533 | 2017-04-03 | ||
| PCT/EP2018/058034 WO2018184964A1 (en) | 2017-04-03 | 2018-03-29 | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ756507A true NZ756507A (en) | 2025-06-27 |
| NZ756507B2 NZ756507B2 (en) | 2025-09-30 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269395B1 (en) | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 | |
| JP2019533441A5 (en) | ||
| CN111148761B (en) | Multispecific antibodies and methods of preparing and using them | |
| FI3177643T5 (en) | Bispecific t cell activating antigen binding molecules | |
| CA2957462C (en) | Cd3 binding domain | |
| JP7853916B2 (en) | immune complex | |
| HRP20200306T1 (en) | Bispecific t cell activating antigen binding molecules specific to cd3 and cea | |
| JP2019502712A5 (en) | ||
| PE20221585A1 (en) | ANTI-ANTIGEN-4 ANTIBODY ASSOCIATED WITH THE CYTOTOXIC T LYMPHOCYTE (CTLA-4) AND USE THEREOF | |
| JP2021507698A5 (en) | ||
| US12054552B2 (en) | Humanized anti-IL-1R3 antibody and methods of use | |
| CA3219181A1 (en) | Il-21 polypeptides and targeted constructs | |
| CA3205670A1 (en) | Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2 | |
| JP2021512613A5 (en) | ||
| CN119546343A (en) | Combination of cytokine fusion protein and CD8 antigen binding molecule | |
| JP2024542235A5 (en) | ||
| NZ756507B2 (en) | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 | |
| RU2024112625A (en) | NEW INTERLEUKIN-7 IMMUNOCONJUGATES | |
| JP2022028645A5 (en) | ||
| NZ766556B2 (en) | Bispecific t cell activating antigen binding molecules | |
| NZ730442A (en) | T cell activating bispecific antigen binding molecules agiant folr1 and cd3 | |
| NZ730442B2 (en) | T cell activating bispecific antigen binding molecules agiant folr1 and cd3 | |
| NZ807704A (en) | Bispecific antigen-binding molecules and methods of use | |
| KR20260062933A (en) | Anti-γδ TCR Antibody and Its Uses | |
| CN121399159A (en) | Engineered bispecific molecules and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 MAR 2027 BY ANAQUA SERVICES Effective date: 20260220 |